Cathy Eng, MD, FACP, FASCO, discusses the types of patients who should be tested for biomarkers in the anal cancer space.
Cathy Eng, MD, FACP, FASCO
Advertisement
Articles by Cathy Eng, MD, FACP, FASCO
Cathy Eng, MD, FACO, FASCO, discusses how biomarkers are being explored to aid the treatment of anal cancers.
Cathy Eng, MD, FACP, FASCO, reviews the case of a 68-year-old diagnosed with metastatic NTRK fusion-positive colon cancer and shares treatments options.
Advertisement
Latest Updated Articles
A 68-Year-Old Woman with Metastatic NTRK Fusion-Positive Colon CancerPublished: May 4th 2020 | Updated:
NTRK-Targeted Therapy for Patients With Colon CancerPublished: May 4th 2020 | Updated:
NTRK-Targeted Therapy in Colon Cancer: Dosing and ManagementPublished: May 4th 2020 | Updated:
Testing for NTRK Fusion–Positive Metastatic Colon CancerPublished: May 4th 2020 | Updated:
Case-Based Overview: NTRK Fusion–Positive mCRCPublished: May 4th 2020 | Updated:
NTRK Fusion–Positive Colon Cancer: Final ThoughtsPublished: May 4th 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
